Ranexa (Menarini)



New Product
HKPharm J Volume 30 (2), May-Aug-2023 (2023-12-21): P.60

Ranolazine inhibits sodium and potassium ion channel currents. It has been shown to exert weak activity on L-type calcium channels making it a weak direct vasodilator and exerts minimal direct effects on atrioventricular nodal conduction. Some additional mechanisms have been elucidated. Ranolazine exerts antagonistic activity towards the alpha 1 and beta 1 adrenergic receptors and inhibition of fatty acid oxidation.

 

Ranexa

(Menarini)

edited by Lucilla Leung

 

Active Ingredients

Ranolazine

 

Pharmacological Properties

Ranolazine inhibits sodium and potassium ion channel currents. It has been shown to exert weak activity on L-type calcium channels making it a weak direct vasodilator and exerts minimal direct effects on atrioventricular nodal conduction. Some additional mechanisms have been elucidated. Ranolazine exerts antagonistic activity towards the alpha 1 and beta 1 adrenergic receptors and inhibition of fatty acid oxidation.

 

Indications

Add-on therapy for the symptomatic treatment of adult patients w/ stable angina pectoris who are inadequately controlled or intolerant to 1st-line antianginal therapies (e.g. β-blockers &/or Ca antagonists).

 

Dosage Forms and Strengths

Each tablets contains 375 mg ranolazine in a prolong release tablet.

Each tablets contains 500 mg ranolazine in a prolong release tablet.

Each tablets contains 750 mg ranolazine in a prolong release tablet.

 

Administration

Adult

Initially 375 mg twice daily. After 2-4 week, the dose should be titrated to 500 mg bd, and according to patient's response, further titrated to a maximum 750 mg twice daily.

 

Contraindications

Hypersensitivity.

Severe renal impairment (CrCl <30 mL/min).

Moderate or severe hepatic impairment.

Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazole, posaconazole, HIV PIs, clarithromycin, telithromycin, nefazodone).

Concomitant administration of class Ia (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.

 

Interactions

Increased plasma conc w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazole, posaconazole, HIV PIs, clarithromycin, telithromycin, nefazodone, grapefruit, diltiazem, erythromycin, fluconazole); P-gp inhibitors (e.g. ciclosporin, verapamil); CYP2D6 inhibitors (e.g. paroxetine). Decreased steady-state conc w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarb, carbamazepine, St. John's wort). Increased plasma conc of P-gp substrates; sensitive CYP3A4 substrates (e.g. simvastatin, lovastatin) & CYP3A4 substrates w/ a narrow therapeutic range (e.g. ciclosporin, tacrolimus, sirolimus, everolimus); metoprolol or other CYP2D6 substrates (e.g. propafenone & flecainide or, to a lesser extent, TCAs & antipsychotics); digoxin; atorvastatin. Increased plasma exposure of metformin (OCT2 substrate). Caution during co-administration w/ CYP2B6 substrates (e.g. bupropion, efavirenz, cyclophosphamide). Increased possible risk of ventricular arrhythmias w/ other drugs known to prolong the QTc interval e.g. certain antihistamines (e.g. terfenadine, astemizole, mizolastine), certain antiarrhythmics (e.g. quinidine, disopyramide, procainamide), erythromycin, & TCAs (e.g. imipramine, doxepin, amitriptyline).

 

Adverse Reactions

Dizziness, headache; constipation, vomiting, nausea; asthenia.

 

Dosage Available

Ranexa  Prolonged-Release Tablets 375 mg in the pack of 60’s.

Ranexa  Prolonged-Release Tablets 500 mg in the pack of 60’s.

Ranexa  Prolonged-Release Tablets 750 mg in the pack of 60’s.

 

Forensic classification

P1S1S3


2023-12-21 於2021月03月11日

Ranexa

(Menarini)

edited by Lucilla Leung

 

Active Ingredients

Ranolazine

 

Pharmacological Properties

Ranolazine inhibits sodium and potassium ion channel currents. It has been shown to exert weak activity on L-type calcium channels making it a weak direct vasodilator and exerts minimal direct effects on atrioventricular nodal conduction. Some additional mechanisms have been elucidated. Ranolazine exerts antagonistic activity towards the alpha 1 and beta 1 adrenergic receptors and inhibition of fatty acid oxidation.

 

Indications

Add-on therapy for the symptomatic treatment of adult patients w/ stable angina pectoris who are inadequately controlled or intolerant to 1st-line antianginal therapies (e.g. β-blockers &/or Ca antagonists).

 

Dosage Forms and Strengths

Each tablets contains 375 mg ranolazine in a prolong release tablet.

Each tablets contains 500 mg ranolazine in a prolong release tablet.

Each tablets contains 750 mg ranolazine in a prolong release tablet.

 

Administration

Adult

Initially 375 mg twice daily. After 2-4 week, the dose should be titrated to 500 mg bd, and according to patient's response, further titrated to a maximum 750 mg twice daily.

 

Contraindications

Hypersensitivity.

Severe renal impairment (CrCl <30 mL/min).

Moderate or severe hepatic impairment.

Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazole, posaconazole, HIV PIs, clarithromycin, telithromycin, nefazodone).

Concomitant administration of class Ia (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.

 

Interactions

Increased plasma conc w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazole, posaconazole, HIV PIs, clarithromycin, telithromycin, nefazodone, grapefruit, diltiazem, erythromycin, fluconazole); P-gp inhibitors (e.g. ciclosporin, verapamil); CYP2D6 inhibitors (e.g. paroxetine). Decreased steady-state conc w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarb, carbamazepine, St. John's wort). Increased plasma conc of P-gp substrates; sensitive CYP3A4 substrates (e.g. simvastatin, lovastatin) & CYP3A4 substrates w/ a narrow therapeutic range (e.g. ciclosporin, tacrolimus, sirolimus, everolimus); metoprolol or other CYP2D6 substrates (e.g. propafenone & flecainide or, to a lesser extent, TCAs & antipsychotics); digoxin; atorvastatin. Increased plasma exposure of metformin (OCT2 substrate). Caution during co-administration w/ CYP2B6 substrates (e.g. bupropion, efavirenz, cyclophosphamide). Increased possible risk of ventricular arrhythmias w/ other drugs known to prolong the QTc interval e.g. certain antihistamines (e.g. terfenadine, astemizole, mizolastine), certain antiarrhythmics (e.g. quinidine, disopyramide, procainamide), erythromycin, & TCAs (e.g. imipramine, doxepin, amitriptyline).

 

Adverse Reactions

Dizziness, headache; constipation, vomiting, nausea; asthenia.

 

Dosage Available

Ranexa  Prolonged-Release Tablets 375 mg in the pack of 60’s.

Ranexa  Prolonged-Release Tablets 500 mg in the pack of 60’s.

Ranexa  Prolonged-Release Tablets 750 mg in the pack of 60’s.

 

Forensic classification

P1S1S3

Related Articles:








HKPharmJ

Tel: 23763090

Email: editor@hkpj.org

Room 1303, Rightful Centre, 12 Tak Hing Street, Jordon, Kowloon, Hong Kong